Introduction
Erythropoietin (EPO), the erythropoietic hormone, is the main treatment option for several types of anemia, including those related to cancer. The function of EPO is regulated by activation of its receptor (EPO-R) on erythroid progenitors, thereby promoting the anti-apoptotic and survival signaling pathways. Recent studies have demonstrated that the functions of EPO are not limited to erythroid cells, and that EPO displays non-erythroid effects that are also related to antiapoptotic processes, such as in heart failure improvement and neuroprotection (1) . Ongoing studies in our laboratory have demonstrated anti-neoplastic, immunomodulatory functions of EPO that were primarily observed in multiple myeloma (MM) patients receiving recombinant human EPO (rHuEPO) treatment for their anemia. This phenomenon was revealed unexpectedly when rHuEPO treatment to these patients not only elevated their hemoglobin (Hb) levels, but also prolonged their survival rates and quality of life (2) . Further studies showed that treatment of MM patients with rHuEPO was actually associated with a marked improvement of various immunological parameters and functions (3) . Analysis of murine MM models reinforced these data and pointed to anti-neoplastic activities of EPO, mediated by improved CD8 lymphocyte functions (4, 5) . In parallel, when assessing the humoral compartment of the immune system, we found that EPO treatment resulted in increased immunoglobulin production in antigen-injected mice, and enhanced lipopolysaccharide (LPS)-mediated splenocyte proliferation (6) .
Since EPO-Rs were not detectable in lymphocytes (3), we considered the possibility that other cells that do express the receptor may act as mediators of EPO function. Our search for possible mechanisms of EPO immunomodulatory effects led us to the novel discovery that dendritic cells (DCs) express the EPO-R, and that stimulation with EPO enhances their survival and function (7, 8) . Studies in murine models showed that EPO increased the splenic DC Based on these findings, we hypothesized that macrophages are also potential targets of EPO. This would be an important discovery, since macrophages and DCs have common progenitors (9) , and macrophages are also powerful antigen-presenting cells and serve as key effectors of the innate immune response (10, 11) . The current study was designed to determine whether macrophages express EPO-Rs and whether they are affected directly by EPO. We focused on examining the effects of EPO on macrophage phenotype and functions, under both in-vivo and in-vitro experimental conditions.
Design and Methods

Mice
Female mice of the inbred C57BL strain, aged 8-12 weeks, were obtained from the TelAviv University Animal Breeding Center. They were used to generate bone marrow-derived macrophages (BMDM) and for the EPO-injected mouse model. The transgenic mice overexpressing HuEPO (tg6) have been previously described (6, 12) . Female tg6 mice and their wild type (wt) littermates, aged 3-5 months, were used for experiments with this murine model.
Mouse handling and the experimental procedures were approved by the Institutional Animal Care and Use Committee of the Tel-Aviv University (number M-07-068).
Reagents
GMP-manufactured sterile syringes of rHuEPO (Eprex®) as used for patient care were kindly provided by Janssen Cilag, Israel, and employed throughout this study, thus ensuring the critically assured absence of toxins in the rHuEPO preparation. LPS from the E. coli strain 0127:B8 (Sigma) was reconstituted in sterile double distilled water (DDW) at 1 mg/ml stock solution and kept at -20°C. Anti human EPO Ab -MAB287 (R&D systems, USA) was reconstituted in phosphate buffered solution (PBS) at 1 mg/ml solution and kept at -20°C.
Preparation of murine splenocytes
The mice were sacrificed by cervical dislocation and their spleens were immersed and forced through 200-m pore-size wire mesh using the plunger from a 5 ml syringe to produce a single cell suspension. The cells were sedimented by centrifugation, and erythrocytes were lysed by hypotonic shock (10 s in sterile DDW), followed by the addition of 0.1 volume of _10 HBSS.
Splenocytes were then prepared for flow cytometry analysis.
Isolation of macrophages from the peritoneal exudate
To induce nonspecific inflammatory exudates, mice were injected intraperitoneally (i.p.) with 1 ml of 3% thioglycollate (Sigma, Israel). These mice were sacrificed 3 days later and all the peritoneal exudate cells were obtained by injecting 10 ml of ice-cold PBS into the peritoneal cavity. After a gentle massage, the fluid was harvested and the cells were centrifuged and washed before further use.
Generation of bone marrow-derived macrophages
Preparation of BM cell cultures was based on the protocol described by Boltz-Nitulescu et al. (13) . Briefly, BM cells were isolated from femurs and tibias of the experimental mice. 
Flow cytometry analysis
The following fluorescence-conjugated antibodies were used: PE CD11b (Miltenyi 
Reverse transcription and polymerase chain reaction analysis
All the procedures were performed according to the manufacturer's instructions. Total RNA was isolated from 7-day cultures of pure untreated BMDMs using the TRIzol reagent (Invitrogen). Reverse transcription was performed using MMLV Reverse Transcriptase (Promega) from 1-2 !g of total RNA. Following cDNA synthesis, PCR was performed using Taq polymerase (Biolabs) for EPO-R or ! actin transcripts, using oligonucleotide primers derived from the murine EPO-R (forward and reverse primers derived from EPO-R exons 1 and 2, respectively) and ! actin sequences: EPO-R forward -5' ATGGACAAACTCAGGGTGC 3', reverse -5' CTAGGAGCAGGCCACATA 3'; actin forward -5' TTCTTTGCAGCTCCTTCGTTGCCG 3', reverse -5' TGGATGGCTACGTACATGGC TGGG 3'.
Bone marrow-derived macrophages for biochemical analysis
The cells were starved for 1 h at 37 o C by incubating them in DMEM medium without any supplements, after which 50 U/ml rHuEPO was added to the cells at different time points, as specified. In order to neutralize EPO activity with anti human EPO Ab, 50 U/ml rHuEPO rHuEPO and 10 µg/ml of the Ab were incubated for 1 h at 37 o C, prior to their addition to the cells. Phosphatase inhibitors (2 mM ZnCl 2 , 2 mM Vanadate, 50 mM NaF, and 20 mM Na 4 P 2 O 7 )
were then added on ice, and the cells were scraped off and collected. The cells were centrifuged at 14,000 rpm and extracted as described below.
Cytoplasmic and nuclear cell extracts were prepared as followed. The cell pellets were resuspended in buffer A -0.1 mM EDTA, 10 mM KCl, and 10 mM HEPES (pH 7.9), to which a protease inhibitor cocktail (CompleteTM protease inhibitors; Roche Diagnostics) was freshly added, and incubated on ice for 10 min. The cells were lysed by adding 0.75% Nonidet P-40, and the lysate was then kept on ice for 5 min with repeated vortexing. The lysate was centrifuged at 5,000 rpm for 5 min to pellet the nuclei, and the supernatant (cytoplasmic extract) was stored at -80°C. The nuclear pellets were first washed in cold PBS and then resuspended in buffer C consisting of 1 mM EDTA, 0.4 M NaCl, and 20 mM HEPES (pH 7.9), with fresh addition of a protease inhibitor cocktail as mentioned above, and incubated for 15 min on ice with repeated vortexing. The suspensions were clarified by centrifugation at 14,000 rpm for 10 min. The supernatants were recovered as nuclear extracts and stored at _80 °C.
Whole cell extracts were prepared as described elsewhere (14) . The cells were lysed at 4 o C in lysis buffer (50 mM Tris pH 7.4, 1% Triton X-100, 5 mM iodoacetamide, 5 mM EDTA, and 150 mM NaCl) containing phosphatase and protease inhibitors. Lysates were spun at 14,000 rpm for 10 min and supernatants were recovered and stored at _80°C.
Immunoblotting
All supernatants were separated on 10% SDS-PAGE and transferred onto a nitrocellulose membrane filter. The nitrocellulose membrane was incubated with the following antibodies: 
Cytokine detection
Supernatants from BMDM cultures were collected after 24 h of incubation with LPS in the presence or absence of rHuEPO, and then analyzed for IL-12 p70 (IL-12) and IL-10.
Cytokine levels were determined by ELISA kits (Peprotech) according to the manufacturer's instructions.
Nitric oxide secretion
Supernatants from BMDM were harvested after 24 h of culture, and levels of NO were measured as the nitrite concentration by mixing equal volumes of culture supernatants (40 !l)
and Griess reagent (Sigma). Nitrite concentrations were determined by comparing the absorbance values (at 540 nm) of the test samples with a standard curve generated by serial dilutions of 100 !M sodium nitrite.
Statistical analysis
Comparisons between data of the control treatment versus data from EPO treatment were performed using Student's t-test. p values less than 0.05 were considered to indicate statistical significance.
Results
Since macrophages are a highly heterogeneous population, with multiple functions and diverse phenotypes (15), we chose to explore the effects of EPO on macrophages that are steadystate residents in the spleen and can be easily identified, as well as macrophages induced by thioglycollate in the peritoneum and those generated in-vitro from bone marrow progenitors The in-vivo effects of EPO were examined under two experimental models. The first model consisted of rHuEPO-injected mice, with diluent-injected mice serving as controls. The second model consisted of the tg6 transgenic mice over-expressing human EPO (6, 12) , with their wt littermates serving as controls. Mice spleens were harvested and phenotyped by flow cytometry analysis.
In-vivo effects of erythropoietin on splenic macrophages
Splenic macrophages were identified by expression of the pan macrophage marker F4/80, which is associated with macrophage differentiation (9, 16) . Further analysis of the F4/80-positive cells was performed to assess the expression of CD11b, a marker of macrophage activation, and MHC class II and CD80, markers of antigen presentation (11, 17) . The proportion of cells expressing the F4/80 cell surface marker indicated that both the rHuEPO-injected mice and, to a larger extent, the tg6 mice, exhibited a significant increase in the splenic macrophage population compared to their respective control groups ( Figure 1A+B ). Moreover, we found increased proportions of splenic macrophages (F4/80 + cells) expressing both CD80 and MHC class II markers ( Figure 1C ) in the rHuEPO-injected and the tg6 mice. However, a significant increase in the number of splenic macrophages expressing CD11b was observed only in the tg6 mice ( Figure 1C ), suggesting that EPO affects this population in a dose-dependent manner. Of 
In-vivo effects of erythropoietin on the peritoneal inflammatory macrophages
In order to determine whether EPO can affect the function of inflammatory macrophages,
we assessed activated peritoneal macrophages induced by thioglycollate administration to the peritoneum in both rHuEPO-injected and tg6 mice. The peritoneal macrophages were identified by CD11b expression. The cell surface expression of CD11b, F4/80, MHC class II and CD80 molecules increased significantly in both the rHuEPO-injected and tg6 mice compared to their control counterparts ( Figure 2A+B ), indicating that excessive availability of EPO led to an enhanced activation status of the macrophages. We then investigated the phagocytic ability of the macrophages using the functional assay of uptake of E. coli bacteria. Both experimental models showed enhanced macrophage phagocytic activity of E. coli bacteria ( Figure 2C ). It would therefore appear that EPO may lead to improved activation and function of the peritoneal inflammatory macrophages. Taken together, excessive availability of EPO resulted in enhancement of the pro-inflammatory phenotype and function of both splenic steady-state and inflammatory-induced peritoneal macrophages. The results of these in-vivo models thus showed that macrophages are, indeed, influenced by EPO.
In-vitro studies on bone marrow-derived macrophages Erythropoietin receptor expression and activation in bone-marrow-derived macrophages
We then investigated macrophages derived in-vitro from the mouse bone marrow cultures in order to determine if EPO can affect macrophages directly. We first investigated whether BMDM expressed the EPO-R, and subsequent RT-PCR analysis demonstrated that EPO-R mRNA is indeed expressed in these cells ( Figure 3A) . We further investigated EPO-R-associated signaling in the BMDMs. Activation of the signal transducer and activator of transcription (STAT) pathways, specifically STAT5, comprise an essential step in the EPO-R signaling cascade (18) . Therefore, we tested whether EPO treatment has any effect on phosphorylation of the STATs. BMDMs were treated in-vitro with rHuEPO and subjected to immunoblot analysis.
Following in-vitro EPO treatment, we detected STAT5, STAT3 and STAT1 phosphorylation in the BMDMs ( Figure 3B ). Thus, involvement of the STAT pathways, specifically STAT5, implies that EPO-R is activated following EPO treatment.
We then examined whether EPO treatment in-vitro can also trigger signaling pathways that are known to participate in macrophage activation, including MAPK, PI3K and NFkB (19) .
As displayed in Figure 3C , in-vitro EPO treatment to BMDMs resulted in phosphorylation of ERK2 and AKT and translocation of p65 to the nucleus. The inhibition of EPO-,mediated STAT5 activation by the anti human EPO Ab, ensure EPO specificity of the above mentioned signaling pathways ( Figure 3D ). It should be noted that the background stimulation in the presence of antibody alone could derive from FC-mediated activation of the BMDMs which harbor an Fc receptor. The specificity of the antibody towards EPO, was verified by the lack of effect on GMCSF mediated activation of STAT5 (data not shown).
We could therefore conclude that exposure of BMDM to EPO results in activation of the MAPK, PI3K and NFkB signaling pathways.
Erythropoietin effects on the bone-marrow-derived macrophage phenotype and function
We examined whether EPO treatment in-vitro can affect BMDM function. BMDMs were cultured in-vitro with or without rHuEPO for 24 h. E. coli phagocytosis and NO secretion assays were performed in order to assess the innate functions of the BMDMs. Macrophages and DCs both develop from common progenitors and share similar surface markers (20, 21) . Together with their many functions relating to the innate immune response, macrophages also display antigen presentation activities, although they are less potent than DCs (17) , which have also been viewed as a subtype of macrophages (22) .
Previous studies have described the effects of EPO on certain macrophage populations.
The tg6 mice have been reported to have increased populations of liver and duodenal mucosa macrophages (23, 24) , and the liver macrophages in tg6 mice also displayed enhanced erythrophagocytic activity (24) . Expression of EPO-R was shown in wound-healing macrophages, and EPO enhanced the activity of these macrophages (25). We employed a variety of experimental models that had excessive availability of EPO in the search of possible effects of EPO on macrophages. These models included in-vivo administration of EPO, transgenic mice over-expressing rHuEPO, as well as direct in-vitro exposure of macrophages to EPO. The EPOdriven increase in the splenic macrophage levels (CD11b, CD80 and MHC class II expression)
could result from enhanced proliferation of macrophage progenitors or the prolonged viability of the existing macrophages. We observed similar effects of EPO on the splenic DC population in previous studies (8), suggesting that the activities of EPO could be related to an effect on the common DC and macrophage progenitors. Notably, EPO effects on both macrophages and DCs were more profound in the tg6 mice, probably due to the continuous exposure to high EPO levels.
The effect of EPO on macrophages was also evident in the peritoneal inflammatory macrophages. Here, EPO treatment enhanced macrophage activation as expressed by the augmented expression of CD11b, F4/80, CD80 and MHC class II and the improved phagocytic function. Notably, unlike the splenic macrophages, EPO treatment was not associated with an increase of the total number of the peritoneal macrophages (data not shown). As such, these findings suggest that EPO modulates peritoneal macrophage activity, but not migration of the macrophages towards the inflamed peritoneum.
The in-vitro administration of EPO enabled us to determine whether EPO can directly affect the macrophages, as well as to assess EPO-driven cellular events. BMDMs were chosen for the in-vitro studies based on the RT-PCR analysis that showed mRNA expression of EPO-R.
The RT-PCR method was selected for this analysis due to the low levels of endogenous cellular EPO-R (26) and the fact that the anti-murine EPO-R antibodies that we routinely use in our studies (14) could not detect the EPO-R protein (data not shown).
The functionality of the BMDM EPO-R was inferred by the EPO-mediated activation of the STAT5, STAT3 and STAT1 pathways in these cells. The STAT5 pathway is considered to be the central signaling pathway activated by the EPO-R and crucial for erythropoiesis (18) . The role of STAT1 in erythropoiesis is less clear (27) , although it does play an essential role in macrophage pro-inflammatory activation (1). Interestingly, we detected EPO-driven STAT3 activation but not STAT1 or STAT5 in DCs (8). STAT3, similar to STAT1, is not essential for erythropoiesis (27) , but it still plays a role in DC development (28) . Thus, we assume that EPOmediated activation of the different STAT subtypes is determined by the cell type and/or environment, enabling STAT3 activation in DCs and STAT1 STAT3 and STAT 5 activation in macrophages.
Following EPO treatment, the BMDMs also exhibited activation of the PI3K, MAPK and NFkB pathways. The activation of these pathways is pivotal in macrophage inflammatory function, including cytokine secretion and phagocytosis (29, 30) . These pathways are also essential in the EPO-R activation of both erythroid (18) and non-erythroid cells (31, 32) .
Notably, EPO treatment that activated signaling pathways did not enhance macrophage survival or proliferation (data not shown).
In-vitro EPO-mediated activation of the BMDMs led to a pro-inflammatory phenotype and function of the cells. This was evident through increased expression of F4/80, CD11b and CD80, elevated phagocytosis and increased NO secretion following EPO treatment. Furthermore, the EPO-dependent elevated IL-12 and decreased IL-10 secretion suggest that EPO treatment not only enhances the pro-inflammatory status of the macrophages, but that it can also shift the macrophages typing to M1. Importantly, M1 macrophages are considered as being effector cells that enhance the TH1 response, and they can enable anti-neoplastic activity (17) . Thus, it is In conclusion, we demonstrated that EPO can directly affect macrophages, leading to a pro-inflammatory activity and function. We propose that the immunomodulatory activities of EPO are mediated, at least in part, by macrophages and DCs.
Authorship and Disclosures
LL designed and performed the research, analyzed data and wrote the paper; GT performed research and analyzed data; MG contributed transgenic mice and data analysis; DN and MM designed research, analyzed data and wrote the paper. The authors declare no competing financial interests. and total STAT5 levels are depicted, NT -non treated; Ab -anti human EPO Ab.
Immunoblots represent one of at least three independent experiments, displaying similar results. 
